The University of Chicago Header Logo

Connection

Peter Sand to Middle Aged

Back to Details
This is a "connection" page, showing publications Peter Sand has written about Middle Aged.
Peter Sand
Connection Strength
1.418
Middle Aged
  1. Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study. Urology. 2021 11; 157:71-78.
    View in: PubMed
    Score: 0.050
  2. A Comparison of Sacrospinous Hysteropexy Augmented With Polypropylene Mesh Versus Human Dermis at 12-Month Follow-up: An Ambidirectional Study. Female Pelvic Med Reconstr Surg. 2020 10; 26(10):607-611.
    View in: PubMed
    Score: 0.048
  3. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. Int Urogynecol J. 2019 08; 30(8):1253-1259.
    View in: PubMed
    Score: 0.042
  4. A multicenter, prospective trial to evaluate mesh-augmented sacrospinous hysteropexy for uterovaginal prolapse. Int Urogynecol J. 2015 May; 26(5):743-8.
    View in: PubMed
    Score: 0.032
  5. Sexual function in women with anal incontinence using a new instrument: the PISQ-IR. Int Urogynecol J. 2015 May; 26(5):657-63.
    View in: PubMed
    Score: 0.032
  6. Vesico-ureteral reflux in women with idiopathic high-pressure detrusor overactivity: prevalence, bladder function, and effect on the upper urinary tract. Int Urogynecol J. 2014 Oct; 25(10):1405-10.
    View in: PubMed
    Score: 0.031
  7. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013 Sep; 190(3):958-64.
    View in: PubMed
    Score: 0.028
  8. Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2013 Feb; 24(2):303-11.
    View in: PubMed
    Score: 0.027
  9. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging. 2012 Feb 01; 29(2):119-31.
    View in: PubMed
    Score: 0.026
  10. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012 Feb; 206(2):168.e1-6.
    View in: PubMed
    Score: 0.025
  11. Foreign-body granuloma after injection of calcium hydroxylapatite for type III stress urinary incontinence. Obstet Gynecol. 2011 Aug; 118(2 Pt 2):418-421.
    View in: PubMed
    Score: 0.025
  12. Extrasphincteric perianal fistulae after sacrospinous fixation for apical prolapse. Obstet Gynecol. 2011 Feb; 117(2 Pt 2):438-440.
    View in: PubMed
    Score: 0.024
  13. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60.
    View in: PubMed
    Score: 0.024
  14. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int. 2010 Sep; 106(6):816-21.
    View in: PubMed
    Score: 0.023
  15. Extended-release trospium chloride improves quality of life in overactive bladder. Value Health. 2010 Mar-Apr; 13(2):251-7.
    View in: PubMed
    Score: 0.022
  16. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Dec; 20(12):1431-8.
    View in: PubMed
    Score: 0.022
  17. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jul; 20(7):827-35.
    View in: PubMed
    Score: 0.021
  18. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jun; 20(6):667-75.
    View in: PubMed
    Score: 0.021
  19. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. 2009; 27(4):329-39.
    View in: PubMed
    Score: 0.021
  20. Predictors of persistent detrusor overactivity after transvaginal sling procedures. Am J Obstet Gynecol. 2008 Dec; 199(6):696.e1-7.
    View in: PubMed
    Score: 0.021
  21. Treatment modalities, health care resource utilization, and costs in patients diagnosed with interstitial cystitis. Am J Obstet Gynecol. 2008 Jul; 199(1):71.e1-10.
    View in: PubMed
    Score: 0.020
  22. Association between response to pentosan polysulfate sodium therapy for interstitial cystitis and patient questionnaire-based treatment satisfaction. Curr Med Res Opin. 2008 Aug; 24(8):2259-64.
    View in: PubMed
    Score: 0.020
  23. Cystoscopy for lower urinary tract symptoms in urogynecologic practice: the likelihood of finding bladder cancer. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jul; 19(7):991-4.
    View in: PubMed
    Score: 0.020
  24. Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement. Urology. 2008 Jan; 71(1):57-61.
    View in: PubMed
    Score: 0.020
  25. Detrusor overactivity and urge urinary incontinence following trans obturator versus midurethral slings. Neurourol Urodyn. 2007; 26(1):42-5.
    View in: PubMed
    Score: 0.018
  26. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007 Apr; 99(4):836-44.
    View in: PubMed
    Score: 0.018
  27. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol. 2006 Dec; 195(6):1730-5.
    View in: PubMed
    Score: 0.018
  28. Detrusor overactivity and urge urinary incontinence [corrected] following midurethral versus bladder sling procedures. Am J Obstet Gynecol. 2005 Dec; 193(6):2144-8.
    View in: PubMed
    Score: 0.017
  29. Delivery mode is a major environmental determinant of stress urinary incontinence: results of the Evanston-Northwestern Twin Sisters Study. Am J Obstet Gynecol. 2005 Dec; 193(6):2149-53.
    View in: PubMed
    Score: 0.017
  30. Safety and effectiveness of Colpexin Sphere in the treatment of pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct. 2006 Sep; 17(5):449-54.
    View in: PubMed
    Score: 0.017
  31. Factors influencing the long-term success of periurethral collagen therapy in the office. Int Urogynecol J Pelvic Floor Dysfunct. 2006 Jun; 17(4):346-51.
    View in: PubMed
    Score: 0.017
  32. Do alterations in vaginal dimensions after reconstructive pelvic surgeries affect the risk for dyspareunia? Am J Obstet Gynecol. 2005 May; 192(5):1573-7.
    View in: PubMed
    Score: 0.016
  33. A prospective randomized trial using solvent dehydrated fascia lata for the prevention of recurrent anterior vaginal wall prolapse. Am J Obstet Gynecol. 2005 May; 192(5):1649-54.
    View in: PubMed
    Score: 0.016
  34. Urinary incontinence after multiple gestation and delivery: impact on quality of life. Int Urogynecol J Pelvic Floor Dysfunct. 2005 Sep-Oct; 16(5):334-6.
    View in: PubMed
    Score: 0.016
  35. Site-specific rectocele repair compared with standard posterior colporrhaphy. Obstet Gynecol. 2005 Feb; 105(2):314-8.
    View in: PubMed
    Score: 0.016
  36. Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. Expert Opin Pharmacother. 2004 Nov; 5(11):2351-9.
    View in: PubMed
    Score: 0.016
  37. Foley versus intermittent self-catheterization after transvaginal sling surgery: which works best? Urology. 2004 Jul; 64(1):53-7.
    View in: PubMed
    Score: 0.015
  38. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004 Jul-Aug; 15(4):243-8.
    View in: PubMed
    Score: 0.015
  39. Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide. Urology. 2004 Jun; 63(6):1182-3.
    View in: PubMed
    Score: 0.015
  40. The development of pelvic organ prolapse following isolated Burch retropubic urethropexy. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Nov; 14(5):321-5; discussion 325.
    View in: PubMed
    Score: 0.015
  41. A randomized controlled trial comparing a modified Burch procedure and a suburethral sling: long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Oct; 14(4):229-33; discussion 233.
    View in: PubMed
    Score: 0.015
  42. Urinary incontinence among mothers of multiples: the protective effect of cesarean delivery. Am J Obstet Gynecol. 2003 Jun; 188(6):1447-50; discussion 1450-3.
    View in: PubMed
    Score: 0.014
  43. Protective effect of suburethral slings on postoperative cystocele recurrence after reconstructive pelvic operation. Am J Obstet Gynecol. 2001 Dec; 185(6):1307-12; discussion 1312-3.
    View in: PubMed
    Score: 0.013
  44. Transvaginal bladder neck suspension to Cooper's ligament. Curr Urol Rep. 2001 Oct; 2(5):344-9.
    View in: PubMed
    Score: 0.013
  45. Anterior or posterior sacrospinous vaginal vault suspension: long-term anatomic and functional evaluation. Obstet Gynecol. 2001 Aug; 98(2):199-204.
    View in: PubMed
    Score: 0.013
  46. Comparison of microtransducer and fiberoptic catheters for urodynamic studies. Obstet Gynecol. 2001 Aug; 98(2):253-7.
    View in: PubMed
    Score: 0.013
  47. Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles. Am J Obstet Gynecol. 2001 Jun; 184(7):1357-62; discussion 1362-4.
    View in: PubMed
    Score: 0.012
  48. A prospective randomized study comparing modified Burch retropubic urethropexy and suburethral sling for treatment of genuine stress incontinence with low-pressure urethra. Am J Obstet Gynecol. 2000 Jan; 182(1 Pt 1):30-4.
    View in: PubMed
    Score: 0.011
  49. A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome. Urology. 2019 Sep; 131:77-82.
    View in: PubMed
    Score: 0.011
  50. Anterior Colporrhaphy With and Without Dermal Allograft: A Randomized Control Trial With Long-Term Follow-Up. Female Pelvic Med Reconstr Surg. 2019 May-Jun; 25(3):206-212.
    View in: PubMed
    Score: 0.011
  51. Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence. J Urol. 2019 05; 201(5):967-972.
    View in: PubMed
    Score: 0.011
  52. Effect of a urinary control insert on quality of life in incontinent women. Int Urogynecol J Pelvic Floor Dysfunct. 1999; 10(2):100-5.
    View in: PubMed
    Score: 0.011
  53. Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome. Int Urogynecol J. 2019 10; 30(10):1735-1745.
    View in: PubMed
    Score: 0.011
  54. Is There a Relationship Between Patient-Reported Satisfaction and Persistence on Overactive Bladder Syndrome Pharmacotherapy? Female Pelvic Med Reconstr Surg. 2018 May/Jun; 24(3):237-240.
    View in: PubMed
    Score: 0.010
  55. Pelvic floor electrical stimulation for genuine stress incontinence: who will benefit and when? Int Urogynecol J Pelvic Floor Dysfunct. 1998; 9(5):265-70.
    View in: PubMed
    Score: 0.010
  56. Incisional hernia after suprapubic catheterization. Obstet Gynecol. 1997 May; 89(5 Pt 2):844-6.
    View in: PubMed
    Score: 0.009
  57. Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study. Int Urogynecol J. 2017 Sep; 28(9):1335-1340.
    View in: PubMed
    Score: 0.009
  58. The evaluation and management of hematuria in women. Int Urogynecol J Pelvic Floor Dysfunct. 1997; 8(3):156-60.
    View in: PubMed
    Score: 0.009
  59. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol. 2017 02; 197(2S):S216-S223.
    View in: PubMed
    Score: 0.009
  60. Pelvic floor stimulation in the treatment of mixed incontinence complicated by a low-pressure urethra. Obstet Gynecol. 1996 Nov; 88(5):757-60.
    View in: PubMed
    Score: 0.009
  61. Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome? Int Urogynecol J. 2017 Mar; 28(3):409-415.
    View in: PubMed
    Score: 0.009
  62. The empty supine stress test as a predictor of intrinsic urethral sphincter dysfunction. Obstet Gynecol. 1996 Jul; 88(1):128-32.
    View in: PubMed
    Score: 0.009
  63. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016 Sep; 196(3):791-800.
    View in: PubMed
    Score: 0.009
  64. Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: a multicenter, placebo-controlled trial. Am J Obstet Gynecol. 1995 Jul; 173(1):72-9.
    View in: PubMed
    Score: 0.008
  65. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2015 Jan; 34(1):37-43.
    View in: PubMed
    Score: 0.007
  66. A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). Int Urogynecol J. 2013 Jul; 24(7):1091-103.
    View in: PubMed
    Score: 0.007
  67. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013 Jun; 189(6):2186-93.
    View in: PubMed
    Score: 0.007
  68. Enhanced interpretability of the PFDI-20 with establishment of reference scores among women in the general population. Neurourol Urodyn. 2012 Nov; 31(8):1252-7.
    View in: PubMed
    Score: 0.007
  69. Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J. 2012 Aug; 23(8):1017-25.
    View in: PubMed
    Score: 0.007
  70. Two unusual presentations of bladder diverticula. Obstet Gynecol. 2011 Aug; 118(2 Pt 2):415-417.
    View in: PubMed
    Score: 0.006
  71. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011 Sep; 30(7):1214-9.
    View in: PubMed
    Score: 0.006
  72. Simple standing incremental cystometry as a screening method for detrusor instability. Obstet Gynecol. 1991 Mar; 77(3):453-7.
    View in: PubMed
    Score: 0.006
  73. Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin. 2011 May; 27(5):921-30.
    View in: PubMed
    Score: 0.006
  74. Nongenetic factors associated with stress urinary incontinence. Obstet Gynecol. 2011 Feb; 117(2 Pt 1):251-255.
    View in: PubMed
    Score: 0.006
  75. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) & grafts in female pelvic floor surgery. Int Urogynecol J. 2011 Jan; 22(1):3-15.
    View in: PubMed
    Score: 0.006
  76. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. Neurourol Urodyn. 2011 Jan; 30(1):2-12.
    View in: PubMed
    Score: 0.006
  77. The prognostic significance of augmentation of urethral closure pressure and functional length. Int J Gynaecol Obstet. 1990 Oct; 33(2):135-9.
    View in: PubMed
    Score: 0.006
  78. Nonsurgical treatment of detrusor overactivity in postmenopausal women. J Reprod Med. 1990 Aug; 35(8):758-64.
    View in: PubMed
    Score: 0.006
  79. Urge incontinence: estimating environmental and obstetrical risk factors using an identical twin study. Int Urogynecol J. 2010 Aug; 21(8):939-46.
    View in: PubMed
    Score: 0.006
  80. Urinary frequency and urgency. Obstet Gynecol Clin North Am. 1989 Dec; 16(4):883-96.
    View in: PubMed
    Score: 0.006
  81. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009 Dec; 63(12):1715-23.
    View in: PubMed
    Score: 0.006
  82. Arcus-anchored acellular dermal graft compared to anterior colporrhaphy for stage II cystoceles and beyond. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Oct; 20(10):1265-71.
    View in: PubMed
    Score: 0.005
  83. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr; 181(4):1764-72.
    View in: PubMed
    Score: 0.005
  84. The effect of retropubic urethropexy on detrusor stability. Obstet Gynecol. 1988 Jun; 71(6 Pt 1):818-22.
    View in: PubMed
    Score: 0.005
  85. Impact of hysterectomy on stress urinary incontinence: an identical twin study. Am J Obstet Gynecol. 2008 May; 198(5):565.e1-4.
    View in: PubMed
    Score: 0.005
  86. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 Mar; 71(3):449-54.
    View in: PubMed
    Score: 0.005
  87. Incontinence history as a predictor of detrusor stability. Obstet Gynecol. 1988 Feb; 71(2):257-60.
    View in: PubMed
    Score: 0.005
  88. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007 Dec; 178(6):2488-94.
    View in: PubMed
    Score: 0.005
  89. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4.
    View in: PubMed
    Score: 0.005
  90. Supine urethroscopic and standing cystometry as screening methods for the detection of detrusor instability. Obstet Gynecol. 1987 Jul; 70(1):57-60.
    View in: PubMed
    Score: 0.005
  91. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology. 2007 May; 69(5):876-80.
    View in: PubMed
    Score: 0.005
  92. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol. 2007; 39(4):1069-77.
    View in: PubMed
    Score: 0.005
  93. The low pressure urethra as a factor in failed retropubic urethropexy. Obstet Gynecol. 1987 Mar; 69(3 Pt 1):399-402.
    View in: PubMed
    Score: 0.005
  94. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov; 28(11):1935-46.
    View in: PubMed
    Score: 0.005
  95. Evaluation of male consorts of women with genital human papilloma virus infection. Obstet Gynecol. 1986 Nov; 68(5):679-81.
    View in: PubMed
    Score: 0.005
  96. Perceptions and behaviours of women with bladder control problems. Fam Pract. 2006 Oct; 23(5):568-77.
    View in: PubMed
    Score: 0.004
  97. Effect of parity on sexual function: an identical twin study. Obstet Gynecol. 2006 Apr; 107(4):765-70.
    View in: PubMed
    Score: 0.004
  98. Risk factors for female anal incontinence: new insight through the Evanston-Northwestern twin sisters study. Obstet Gynecol. 2005 Oct; 106(4):726-32.
    View in: PubMed
    Score: 0.004
  99. The effect of preemptive pudendal nerve blockade on pain after transvaginal pelvic reconstructive surgery. Obstet Gynecol. 2005 Oct; 106(4):782-8.
    View in: PubMed
    Score: 0.004
  100. TVT versus SPARC: comparison of outcomes for two midurethral tape procedures. Int Urogynecol J Pelvic Floor Dysfunct. 2006 Feb; 17(2):125-30.
    View in: PubMed
    Score: 0.004
  101. Successful treatment of Zoon's vulvitis with high potency topical steroid. Int Urogynecol J Pelvic Floor Dysfunct. 2006 Feb; 17(2):178-9.
    View in: PubMed
    Score: 0.004
  102. Chronic pelvic actinomycosis following a bone anchored sling procedure. J Urol. 2004 Jun; 171(6 Pt 1):2381.
    View in: PubMed
    Score: 0.004
  103. Incidence of pubic osteomyelitis after bladder neck suspension using bone anchors. Urology. 2004 Apr; 63(4):704-8.
    View in: PubMed
    Score: 0.004
  104. Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. J Neural Transm Suppl. 2004; (68):147-56.
    View in: PubMed
    Score: 0.004
  105. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003 Aug; 62(2):237-42.
    View in: PubMed
    Score: 0.004
  106. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003 Jun; 78(6):687-95.
    View in: PubMed
    Score: 0.004
  107. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol. 2002; 34(1):43-9.
    View in: PubMed
    Score: 0.003
  108. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001 Apr; 76(4):358-63.
    View in: PubMed
    Score: 0.003
  109. Early-stage ovarian carcinoma presenting with irritative voiding symptoms and urge incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2001; 12(5):342-4.
    View in: PubMed
    Score: 0.003
  110. Update on extracorporeal magnetic innervation (EXMI) therapy for stress urinary incontinence. Urology. 2000 Dec 04; 56(6 Suppl 1):82-6.
    View in: PubMed
    Score: 0.003
  111. Extracorporeal magnetic innervation therapy for stress urinary incontinence. Urology. 1999 Jun; 53(6):1108-11.
    View in: PubMed
    Score: 0.003
  112. [Signs of inflammation and hemorrhage in the rectal mucosa during therapy of rectal constipation with phosphate enemata and bisacodyl rectal tube]. Ugeskr Laeger. 1978 Aug 21; 140(34):2041-4.
    View in: PubMed
    Score: 0.003
  113. Pelvic floor electrical stimulation for the treatment of urge and mixed urinary incontinence in women. Urology. 1997 Dec; 50(6):934-40.
    View in: PubMed
    Score: 0.002
  114. Effectiveness of a urinary control insert in the management of stress urinary incontinence: early results of a multicenter study. Urology. 1996 May; 47(5):629-36.
    View in: PubMed
    Score: 0.002
  115. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996 Jan; 21(1):25-31.
    View in: PubMed
    Score: 0.002
  116. [Alcohol and drug abuse as risk factors for violence and delinquency in schizophrenic patients]. Psychiatr Prax. 1993 Sep; 20(5):172-5.
    View in: PubMed
    Score: 0.002
  117. Unsuccessful Burch retropubic urethropexy: a case-controlled urodynamic study. Am J Obstet Gynecol. 1989 Feb; 160(2):452-8.
    View in: PubMed
    Score: 0.001
  118. A urodynamic appraisal of success and failure after retropubic urethropexy. J Reprod Med. 1987 Sep; 32(9):693-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.